UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________________ to ___________________ Commission File Number: 001-39460 KYMERA THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) De ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39460 KYMERA THERAPEUTICS, INC. (Exact name of Registrant as specified in its Charter) (State or other jurisdiction of incorporation ...

INVENTING NEW MEDICINES W I T H T A R G E T E D P R O T E I N D E G R A D A T I O N February 2022 Forward-looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA) and other federal securities laws. These statements include information about our current and future prospects and our operations and financial results, which are based on currently available information. All statements other than statements of histo ...

INVENTING NEW MEDICINES W I T H T A R G E T E D P R O T E I N D E G R A D A T I O N January 2022 Forward-looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA) and other federal securities laws. These statements include information about our current and future prospects and our operations and financial results, which are based on currently available information. All statements other than statements of histor ...

Commission File Number: 001-39460 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________________ to ___________________ KYMERA THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter ...

INVENTING NEW MEDICINES W I T H TA R G E T E D P R OT E I N D E G R A D AT I O N September 2021 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA) and other federal securities laws. These statements include information about our current and future prospects and our operations and financial results, which are based on currently available information. All statements other than statements of histori ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________________ to ___________________ Commission File Number: 001-39460 KYMERA THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Del ...

业绩总结 - Kymera截至2021年第一季度的现金余额为4.35亿美元，预计可支持运营计划至2025年[8] - Kymera计划在2021年底前启动3个IND（新药申请）和临床试验[8] - Kymera的员工人数约为100人，成立于2016年，股票代码为KYMR[7] 用户数据与市场扩张 - Kymera的管线包括针对多种疾病的多个项目，如KT-474针对特应性皮炎、Hidradenitis Suppurativa和类风湿关节炎等[11] - Kymera与Sanofi的合作包括开发IRAK4降解剂候选药物KT-474（SAR444656），该项目不涉及肿瘤学和免疫肿瘤学领域[12] 新产品与技术研发 - Kymera的目标是开发组织选择性或组织限制性降解剂，以实现新的治疗机会[9] - Kymera的药物开发平台专注于免疫炎症和肿瘤学领域[8] - Kymera的药物降解技术依赖于小分子配体与E3连接酶的结合，目标是实现治疗潜力[18] - 公司在虚拟筛选中评估了约80万种可购买的化合物，并利用云技术在24小时内完成筛选[21] - 通过早期的片段X射线结构和虚拟库评估，成功识别出IC50小于30μM的强效结合剂[28] - STAT3降解剂在多种癌细胞类型中表现出广泛的降解能力，1μM时可实现超过50%的STAT3降解[35] - 公司已识别出600种独特的E3连接酶的表达谱，并建立了E3连接酶图谱以识别新型E3连接酶[37] - 通过SBDD（结构基础药物设计）活动，成功识别出多个E3连接酶配体[29] - 通过对Ligase X的评估，发现其具有配体可结合的口袋，支持后续的药物开发[24] 负面信息与其他策略 - Ligase X在多种癌细胞系中以低水平表达，且在健康组织中表现出限制性表达[25] - Ligase X的HTRF IC50值分别为1.9 mM、2.7 mM和0.75 mM，显示出良好的物理化学性质[31] - Ligase X的分子量小于400，且具有优良的物理性质和溶解度[30]

INVENTING NEW MEDICINES W I T H T A R G E T E D P R O T E I N D E G R A D A T I O N UBS Global Healthcare Virtual Conference May 25, 2021 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA) and other federal securities laws. These statements include information about our current and future prospects and our operations and financial results, which are based on currently available information. All s ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________________ to ___________________ Commission File Number: 001-39460 KYMERA THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) De ...